课题基金 / 基金详情

Cord Blood Stem Cell Transplantation, Hemoglobinopathies

Cord Blood Stem Cell Transplantation, Hemoglobinopathies
脐带血干细胞移植,血红蛋白病
批准号:
6689114
负责人:
JOHN E HEARST
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-15 至 2004-01-14

项目摘要

项目成果

JOHN E HEARST的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):骨髓移植有可能完全治愈血红蛋白病的疾病症状。对镰状细胞病或地中海贫血患者成功应用错配(相关单倍体相同)骨髓移植,需要实现骨髓中的同种异体嵌合并使其稳定,且发病率和死亡率低于现有的错配骨髓移植(BMT)方案。这一目标需要使用更少的全身辐射和更少的药物骨髓消融来支持移植。通过使用补骨脂素光化学处理供体白细胞,混合嵌合骨髓状态已在小鼠中实现并稳定,这些白细胞的增殖能力被阻断,但仍保留其免疫活性。在完全MHC错配的环境下,模型小鼠骨髓移植实验最近证明,在低剂量的清髓辐射条件下,在没有清髓和免疫抑制药物的情况下,S-59(一种补骨脂素)光化学处理(S-59 PCT)的t细胞加回促进和稳定同种异体嵌合,大大降低了移植物抗宿主病(GVHD)的风险。在美国公共卫生服务拨款R01 HL63456“干细胞移植建立同种异体嵌合”的支持下,该项目完成了验证,现在进入开发阶段,最终将导致批准儿科同种异体干细胞移植的临床方案。这一成功是奥克兰儿童医院研究所和Cerus公司之间富有成效的合作的结果。由于脐带血最近已成为儿科骨髓移植的重要干细胞来源,我们设计了一项小鼠脐带血研究,以测试PCT t细胞补充剂在提高脐带血移植安全性方面的价值。这项研究的目的是为镰状细胞病或地中海贫血患儿的临床试验提供临床前支持。在这项应用中,我们建议在小鼠模型中验证脐带血移植,并确定t细胞消耗和Amotosalen光化学处理的t细胞补充剂提供的价值,以提供比传统脐带血干细胞移植(不包括PCT t细胞补充剂)更安全的替代方案。
英文摘要
DESCRIPTION (provided by applicant): Bone marrow transplantation has the potential of providing a complete cure of the disease symptoms of hemoglobinopathies. Successful application of mismatched (related-haploidentical) bone marrow transplantation to patients with sickle cell disease or thalassemia requires that allochimerism be achieved and stabilized in the bone marrow with less morbidity and mortality than is being experienced in existing mismatched bone marrow transplantation (BMT) protocols. This goal requires use of less total body radiation and less drug myeloablation in support of the transplantation. Mixed chimeric bone marrow states have been achieved and stabilized in mice through the use of psoralen photochemically treated donor leukocytes which are blocked in their proliferative capabilities but which retain their immunological activities. Model mouse bone marrow transplantation experiments, in a complete MHC mismatch setting, have recently demonstrated that under low dose myeloablative radiation conditions and in the absence of myeloablative and immunosuppressive drugs, S-59 (a psoralen) photochemically treated (S-59 PCT) T-cell add-backs promote and stabilize allochimerism with greatly reduced risk of graft versus host disease (GVHD). With the completion of this validation through the support of US Public Health Service Grant R01 HL63456, "Stem Cell Transplantation to Establish Allochimerism," this project is now entering a development phase that should ultimately lead to an approved clinical protocol of pediatric allogeneic stem cell transplantation. This success has resulted from a very productive collaboration between Children's Hospital Oakland Research Institute and Cerus Corporation. Because cord blood has recently become an important source of stem cells for pediatric marrow transplant, we have designed a cord blood study in mice that will test the value of PCT T-cell supplements in the improvement of safety in cord blood transplantation. The objective of such a study is to provide pre-clinical support for a clinical trial for pediatric patients with sickle cell disease or thalassemia. In this application, we propose to validate cord blood transplantation in a mouse model and to determine the value provided by T-cell depletion and Amotosalen photochemically treated T-cell supplements in providing a safer alternative to conventional cord blood stem cell transplantation (which does not include PCT T-cell supplements).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Amotosalen PCT of Leukapheresis Units for GvHD Therapy
  • 批准号:
    6787862
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2004
  • 负责人:
    JOHN E HEARST
  • 依托单位:
MINIATURIZED INSTRUMENTATION FOR THE HTS OF DNA REPAIR
  • 批准号:
    6738364
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2004
  • 负责人:
    JOHN E HEARST
  • 依托单位:
Amotosalen PCT of Leukapheresis Units for GvHD Therapy
DNA Repair Inhibition and Cancer Therapy
  • 批准号:
    6691226
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2003
  • 负责人:
    JOHN E HEARST
  • 依托单位:
海外基金